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A new simple, sensitive, cost-effective and reproducible high performance liquid chromatographic 
(HPLC) method for the determination of proguanil (PG) and its metabolites, cycloguanil (CG) and 4-
chlorophenylbiguanide (4-CPB)  in urine and plasma is described. The extraction procedure is a simple 
three-step process that has eliminated the need for costly extraction and evaporation equipment. The 
mobile phase consisted largely of buffer, making the method cheap to run. The calibration plots were 
linear over the concentration range up to 3.0 µg/ml PG, CG and 4-CPB in urine and concentration range 
up to 1000 ng/ml in plasma. The correlation coefficients (r) were of the order of 0.99 and above for PG 
and 4-CPB and 0.98 for CG. The ion pair method was carried out on a 5 µ reversed-phase C-18 column, 
using perchlorate ion as the counter ion and ultra violet detection at 254 nm. The method was 
reproducible with coefficient of variation for PG, CG and 4-CPB, being less than 10% in urine and 
plasma. PG was well resolved from its metabolites, CG and 4-CPB, and the internal standard, 
pyrimethamine. The limit of detection of PG was 10 ng/ml and the recovery was greater than 90% in 
urine and plasma. The analytical method therefore, exhibits good precision and sensitivity and is one of 
the few methods that can detect PG and the two metabolites CG and 4-CPB. The analytical method 
developed in this study was used to determine PG bioavailability after rectal administration in humans.  
 





Proguanil, a synthetic biguanide derivative of pyrimidine, 
is widely used in chemoprophylaxis of malaria. It is 
chronically administered for malaria prophylaxis in sickle 
cell patients in Nigeria. The emergence of chloroquine 
resistant Plasmodium falciparum in our environment has 
led to a resurgence of interest in the use of proguanil 
when daily prophylaxis of malaria is indicated. In addition 
proguanil has found use in combination with other drugs 
such as atovaquone and dapsone in the treatment of 
resistant cases of falciparum malaria (Looareesuwan et 
al., 1996). This renewed interest in the use of proguanil 
makes     it     necessary     to      elucidate      fully      the  
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pharmacokinetics of the drug in biological fluids, which 
requires highly sensitive, accurate and specific method of 
analysis.    
The various methods described for the determination 
of proguanil and its metabolites in the body includes 
colorimetric, microbiological and chromatographic 
methods. The colorimetric and bioassay method of 
analysis as described by (Maegraith et al., 1946 Watkins 
et al., 1987) lacked specificity and sensitivity. They are, 
therefore, of little value in pharmacokinetic studies.  
A chromatographic method reported for the analysis of 
proguanil in the biological fluid is the reversed phase, 
ion-pair high performance liquid chromatographic (HPLC) 
technique developed by Moody et al. (1980) for the 
assay of proguanil in serum. Specific quantitation was 





determination of the metabolites. 
Edstein (1986) reported ion-pair reversed phase 
technique using a 30 x 3.9 mm id column packed with 10 
/m -Bondapak C18. A detection limit of 25 ng/ml was 
reported for cycloguanil and proguanil, but the method 
was unable to detect the second metabolite, 4-CPB, in 
the sample plasma obtained from a human volunteer 
dosed with 200 mg proguanil. Kelley and Fletcher (1986) 
also reported the use of cyanopropyl packed columns 
with an aqueous mobile phase containing ammonium 
formate as the ion-pairing agent. These HPLC methods 
described above were unable to detect 4-CPB in the 
presence of proguanil in plasma samples. 
With more emphasis on off-column sample 
pretreatment of biological samples prior to HPLC 
analysis as a necessary panacea to low level detection 
of drugs in biological fluid, Taylor et al. (1987) employed 
liquid-liquid extraction procedure. It was observed that 
the use of hexane as the sole extracting solvent resulted 
in poor recoveries for cycloguanil and 4-CPB. They made 
a modification of the solvent composition, the solvent 
mixture composed of hexane and isoamyl alcohol (4:1) 
was used. There was a resultant low recovery of both 
cycloguanil and proguanil as compared to earlier report 
by Edstein (1986) but CPB was detected.  
Other workers, who used HPLC method in analyzing 
proguanil and major metabolites in biological fluids, 
utilized the modification of the method of Taylor et al. 
(1987). They could still not resolve the problem of low 
recovery of the metabolites (Chiluba et al., 1987; 
Wattanagoon et al., 1987; Watkins et al., 1987). 
Due to some of these inconsistencies on the analytical 
data of proguanil and inter laboratory differences, the 
report of WHO informal consultation on the use of 
antimalarial drugs (2001) adjudged proguanil to have 
limited pharmacokinetic data in literature. This study 
therefore, set out to develop a simple, cost-effective, 
sensitive and accurate method that can measure 
accurately the concentration of proguanil and its 
metabolites in different biological fluids. 
 
 
MATERIALS AND METHODS 
 
Chemicals, reagents and apparatus 
 
Proguanil hydrochloride powder (ICI), proguanil hydrochloride 
tablets (Zeneca Pharmaceutical, Ltd), cycloguanil powder (ICI), 4-
chlorophenylbiguanide powder (ICI), pyrimethamine powder (BDH), 
ammonium acetate (BDH), perchloric acid   60% w/w  (BDH), 
diethyl ether (BDH), HPLC grade acetonitrile (Sigma Aldrich), 
HPLC grade methanol (Fisher scientific) and acetone (BDH). 220V 
Ultra sonicator (Branso), whirlmixer (Scientific Industries Inc.), table 
centrifuge {Gallenkamp}, precision pipettes (Eppendorf), Pasteur 
pipettes and extraction tube 
 
 
Preparation of stock solutions  
 
Stock solutions containing 100 µg/ml proguanil, cycloguanil and 4-
chlorophenylbiguanide  were  prepared  in  distilled    water,    while  




pyrimethamine, which was used as the internal standard, was 





The Liquid chromatographic system used consisted of a Cecil 1100 
series instrument (Cecil Instrument, Cambridge, England) made up 
of binary pumps fitted with a gradient mixer (Cecil instrument) with 
a system purge and a variable wavelength (200-800 nm) 
ultraviolet-visible detector model CE1200 (Cecil instrument) with a 
18 µL flow cell. Injection was by a Rheodyne model 7725 valve 
(Cotati, California, U.S.A.) fitted with a 20 µL loop. The detector 
output is linked to a CTX Computer (made in Thailand) via a brain-
box inter-phase (Cecil Instrument), which transforms signals from 
the detector to the computer that eventually records the 
chromatograms. The computer system is connected to an LX 300 
printer (Epson). The column used was a Hypersil ODS (C-18) 5µm 
particle size and 250 x 4.6 mm I.D, reversed phase stainless steel 
(Alltech). A mobile phase consisting of methanol : acetonitrile : 
0.5% ammonium acetate (40:5:55) containing 75 mM/L perchloric 
acid was pumped through the column at a flow rate of 1.2 ml/min.  
The pH of the mobile phase was 2.2, and the chromatogram was 





Calibration curve in urine: 1 ml blank urine samples were placed 
in extraction tubes; varying amounts of the stock solutions (100 
µg/ml) of proguanil, cycloguanil and 4-chlorophenylbiguanide were 
added to give calibration curves between 0.1 – 3 g/ml for 
proguanil, 4-chlorophenylbiguanide and cycloguanil.  20 µL of the 
stock solution of the internal standard, pyrimethamine (100 µg/ml), 
was added to each tube.  The urine samples were rendered 
alkaline with 2 M NaOH (0.5 ml) and whirlmixed for 1 min. Then 3 
ml ether was added to each of the samples and whirlmixed for 1 
min after which the tubes were centrifuged at 1500 rpm for 10 min. 
The upper organic layer was aspirated into another tube. The 
extraction with ether was repeated twice. The pooled extract was 
evaporated to dryness in a water bath at 40oC. The residue was 
reconstituted in 100 µL of methanol and whirlmixed before injecting 
20 L onto the HPLC. The peak area ratio was plotted against the 
concentration of each of the compounds injected. The regression 
analysis was carried out with the aid of a computer. 
 
Calibration curve in plasma: To 1 ml blank plasma samples 
placed in centrifuge tubes, varying amounts of the stock solution of 
proguanil, cycloguanil and 4-chlorophenylbiguanide were added to 
give a concentration between 0.05 - 1.0 µg/ml for the three 
compounds. 10 L of the internal standard solution was added to 
each tube. The samples were extracted with ether under alkaline 
conditions as described for urine.  The residue was reconstituted in 




Determination of drug and metabolites in biological samples 
 
Analysis of test urine samples: To 1 ml of urine sample in a 
centrifuge tube, 20 L of the internal standard was added.  PG and 
its metabolites, CG and 4-CPB were extracted under alkaline 
conditions as previously described. The residue was reconstituted 
in 100 L methanol, whirlmixed before 20 L was injected onto the 
HPLC. 
 
Analysis of test plasma samples: To 1 ml of plasma sample in 
extraction tube, 10 L of  the   internal   standard  was  added.  The  




             Table 1. Precision of analytical method in urine. 
 
Coefficient of Variation (%) Precision period Conc. µg/ml No. of samples (n) 
PG CG 4-CPB 
0.5 4 5.78 4.65 3.26 Within-day 
2.0 4 2.47 4.65 3.4 
0.5 4 4.05 4.36 2.16 Day-to-day 




              Table  2. Precision of analytical method in plasma. 
 
Coefficient of Variation (%) Precision period Conc. µg/ml No. of samples (n) 
PG CG 4-CPB 
0.5 4 6.14 8.33 6.15 Within-day 
2.0 4 4.29 9.74 2.78 
0.5 4 3.19 2.95 2.38 Day-to-day 
2.0 4 3.03 8.04 4.30 
 
 
extraction and reconstitution followed as described above before 
injecting 20 L onto the HPLC. 
 
 
Precision studies in plasma and urine 
 
Within-run precision studies: Two sets, each set consisting of 
four centrifuge tubes, were used.  Each tube in the first set 
contained 1 ml of blank sample (urine or plasma) spiked with the 
stock solution of the three compounds to give a concentration of 
0.5 µg/ml.  The second set also contained 1 ml of blank sample 
(urine or plasma) spiked with stock solution of the three 
compounds to give a concentration of 2 µg/ml of each. All the 
samples were then spiked with 20 L of the internal standard 
solution in case of urine and 10 L in the case of plasma. 
Extraction followed under alkaline conditions as earlier described. 
The residue was reconstituted in 100 L methanol, whirlmixed 
before 20 L was injected onto the HPLC. The coefficient of 
variation of each set was computed. 
 
Day-to-day Precision: The procedure above was followed but a 
sample for each set was analyzed daily for 4 days. 
 
 
Recovery studies in plasma and urine 
 
Two sets, each set consisting of four centrifuge, tubes were used. 
Each tube in the first set contained 1 ml of blank sample (urine or 
plasma) spiked with the stock solution of the three compounds to 
give a concentration of 0.5 µg/ml. The second set contained the 
same amount of blank sample spiked to give a concentration of 2 
µg/ml for the three compounds. All the samples were then spiked 
with 20 L of the internal standard solution in the case of urine and 
10 L in the case of plasma. Extraction followed under alkaline 
conditions as described earlier.  The residues were reconstituted in 
100 L methanol and whirlmixed before 20 L was injected onto 
the HPLC. In two other tubes, the stock solutions were diluted in 
such a way as to give 0.5 µg /ml and 2 µg/ml for the three 
compounds.  The two tubes were spiked with 20 µL of the internal 
standard solution in case of urine and 10 µL in the case of plasma. 
To determine the recovery, the peak area ratio of the extraction 
method and direct injection method were compared. 
RESULTS AND DISCUSSION 
 
The HPLC method used for the analysis gave a good 
resolution of proguanil from its two metabolites, 
cycloguanil and 4-chlorophenylbiguanide and the internal 
standard (pyrimethamine). There was no interference 
from endogenous compounds in all the biological 
samples used in the study, thus facilitating accurate 
determination of the drug and its metabolites. The 
method also gave good recoveries for proguanil (>90%) 
and one of the metabolites, CPB (>88%), in urine and 
plasma (Tables 1 and 2). The recoveries for PG and 
CPB were lower but still acceptable in plasma being 87 
and 79%, respectively. But the analytical method, on the 
other hand, showed moderate sensitivity to the major 
metabolite, cycloguanil, leading to its moderate recovery 
(about 70% or less) in urine and plasma. Previous 
workers, who have attempted to quantify proguanil and 
its metabolites using HPLC method, reported poor 
recoveries of cycloguanil and low detection of CPB 
(Eidstein, 1986; Taylor et al., 1987). The poor recovery of 
cycloguanil may not be unconnected with the solvent 
systems employed in the extraction procedure by those 
workers. In this study, the choice of diethyl ether as the 
extracting solvent resulted in some improved recovery of 
cycloguanil compared to previous reports in literature. 
The HPLC method was reproducible with coefficient of 
variation (which is a measure of precision) for proguanil 
and its metabolites, CG and CPB, being less than 10% in 
urine and plasma (Tables 3 and 4). The method, 
therefore, exhibits good precision and sensitivity. The 
analytical method employed in this study is one of the 
few methods that can detect proguanil and the two 
metabolites despite the moderate recovery of CG. 
 




                   Table 3. Results of recovery studies in urine. 
 
Percentage recovery Conc.  
(µg/ml) 
No. of Samples 
(n) PG CG 4-CPB 
0.5 4 94.4 ± 3.4 61.9 ± 4.4 109.5 ± 3.6 
2.0 4 90.3 ± 5.2 66.5 ± 6.3 88.5 ± 4.1 
 
 
                   Table 4. Results of recovery studies in plasma. 
 
Percentage recovery Conc.  
(µg/ml) 
No. of Samples 
(n) PG CG 4-CPB 
0.5 4 90.3 ± 6.6 66.2 ± 7.9 86.8 ± 4.7 
2.0 4 70.9 ± 6.3 70.9 ± 6.3 79.2 ± 7.5 
                 
 
 
y = 0.0002x + 0.0273
R2 = 0.9929
y = 0.0002x + 0.0347
R2 = 0.9658































                           Figure 1. Calibration curves for proguanil (PG), cycloguanil (CG) and 4-chlorophenylbiguanide (4-CPB) in urine. 
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y = 0.0017x - 0.0636
R2 = 0.9952
y = 0.0002x + 0.0071
R2 = 0.9789



































The calibration curve for proguanil was linear with 
correlation coefficient of not less than 0.99 (Figures 1 
and 2) in all the biological samples used in the study. 
The calibration curves were also linear for the two 
metabolites, cycloguanil (R2>0.96) and 4-
chlorophenylbiguanide (R2>0.99), in all the biological 
fluids used in the study. 
This method was used to study proguanil bioavailability 
from suppository in comparison with tablet formulation. 
The detection of measurable level of proguanil and 
metabolites in urine and plasma following the 
administration of the proguanil suppository and tablet to 
all the ten volunteers is an indication that the method is 
selective and sensitive. 
The lower limit of quantitation of PG in urine and 
plasma, which was 10 ng/ml made it possible to monitor 
the unchanged drug for the whole duration of sample 
collection when this method was used to study PG 
bioavailability from suppository formulation in comparison 
to the tablet formulation. The detection of the measurable 
levels of PG, CG and 4-CPB in urine and plasma 
following the administration of the PG suppositories and 
tablets to all volunteers who participated in the study was 






Chiluba EM, Fletcher KA, Price AH (1987). The pharmacokinetics of 
proguanil in human subjects following a single oral dose. Afr. J. Med. 
Sci. Br. 16: 43-46. 
Eidstein MD (1986). Simultaneous measurement of Proguanil and 
Cycloguanil in human plasma by High Pressure Liquid 
Chromatography. J. Chromatogr. Amsterdam, 380: 184-189. 
Kelly JA, Fletcher KA (1986). High Pressure Liquid Chromatography 
method for the determination of proguanil and cycloguanil in 





Looareesuwans S, Viravan C, Webster HK, Kule DE, Hutchinson DB, 
Canfield CJ (1996). Clinical studies of atovaquone alone or in 
combination with other antimalaria drugs in the treatment of acute 
uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54: 62 – 
68. 
Maegreath BG, Tottey MM, Adam ARD, Andrews WH, King JD (1946). 
the absorption and extraction of proguanil in human subject. Ann. 
Trop. Med. Parasitol. 40: 493-506. 
Moody RR, Selkirk AB, Taylor RB (1980). High Performance Liquid 
Chromatography   of   proguanil,   cycloguanil   and   4-chlorophenyl- 
    biguanide using a hydrophobic pairing ion and its application to 
serum assay. J. Chromatogr. 182: 359-367. 
Taylor RB, Moody RR, Ochekpe NA (1987). Determination of proguanil 
and  its  metabolites,  cycloguanil   and   4-chlorophenylbiguanide   in  
 




     plasma, whole blood and urine by High Pressure Liquid 
Chromatography. J. Chromatogr. Amsterdam. 416: 394-399. 
Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE 
(1987). A preliminary pharmacokinetic study of the antimalarialdrugs, 
proguanil and chlorproguanil. J. Pharm. Pharmacol. 39: 261-265. 
Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, 
White NJ (1987). Single dose Pharmacokinetics f proguanil and its 
metabolite in healthy subjects. Br. J. Clin. Pharmacokinet. 24: 775-
780. 
World Health Organisation (2001). Report of a WHO Informal 
Consultation on the use of antimalarial drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
